卵巢癌(OC)是第二常见的妇科恶性肿瘤，通常影响50岁以上的女性，由于75%的病例仅在第III期或IV期才被发现，这是一个糟糕诊断的迹象。尽管腹腔内化疗具有较好的化疗敏感性，但大多数患者会复发并面临死亡。早期检测很困难，治疗也很困难，因为需要通过特定途径给药，存在治疗抵抗、复发以及需要精确靶向癌细胞以减少细胞毒性和副作用的问题。另一方面，经历切除术变得具有挑战性，许多化疗药物表现出耐药性，即多药耐药(MDR)。虽然卵巢癌还有其他治疗选择，本文专注于协同输送技术，该技术通过不同的途径克服癌细胞的耐药性。不同的途径导致卵巢癌发展多药耐药(MDR)，通常涉及泵和非泵机制。重击癌细胞是战胜MDR的重要手段。纳米载体可以绕过细胞膜上的药物外流泵，打击泵机制。纳米载体通过被动或主动靶向增强化疗药物输送到肿瘤部位，从而减少对健康组织的不利副作用，同时通过提高渗透和滞留(EPR)机制来增强药物在肿瘤部位的生物利用度。为了解决传统输送的缺点，本综述试图解释当前的传统治疗，特别是针对特定受体发展的被动和主动靶向药物输送系统(DDSs)来治疗卵巢癌。总之，定制的纳米载体在优化药物输送到细胞内隔室之前，会优化肿瘤内分布。卵巢癌的其他新型治疗可能包括肿瘤疫苗、基因治疗、靶向表观遗传变化和生物靶向化合物。这些特点可能增强治疗效果。版权所有© Bentham Science Publishers，有任何疑问，请发送电子邮件至epub@benthamscience.net。

Ovarian cancer (OC) is the second most common gynaecological malignancy. It typically affects females over the age of 50, and since 75% of cases are only discovered at stage III or IV, this is a sign of a poor diagnosis. Despite intraperitoneal chemotherapy's chemosensitivity, most patients relapse and face death. Early detection is difficult, but treatment is also difficult due to the route of administration, resistance to therapy with recurrence, and the need for precise cancer targeting to minimize cytotoxicity and adverse effects. On the other hand, undergoing debulking surgery becomes challenging, and therapy with many chemotherapeutic medications has manifested resistance, a condition known as multidrug resistance (MDR). Although there are other therapeutic options for ovarian cancer, this article solely focuses on co-delivery techniques, which work via diverse pathways to overcome cancer cell resistance. Different pathways contribute to MDR development in ovarian cancer; however, usually, pump and non-pump mechanisms are involved. Striking cancerous cells from several angles is important to defeat MDR. Nanocarriers are known to bypass the drug efflux pump found on cellular membranes to hit the pump mechanism. Nanocarriers aid in the treatment of ovarian cancer by enhancing the delivery of chemotherapeutic drugs to the tumour sites through passive or active targeting, thereby reducing unfavorable side effects on the healthy tissues. Additionally, the enhanced permeability and retention (EPR) mechanism boosts the bioavailability of the tumour site. To address the shortcomings of conventional delivery, the current review attempts to explain the current conventional treatment with special reference to passively and actively targeted drug delivery systems (DDSs) towards specific receptors developed to treat ovarian cancer. In conclusion, tailored nanocarriers would optimize medication delivery into the intracellular compartment before optimizing intra-tumour distribution. Other novel treatment possibilities for ovarian cancer include tumour vaccines, gene therapy, targeting epigenetic alteration, and biologically targeted compounds. These characteristics might enhance the therapeutic efficacy.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.